# Consensus checked against original sources: Laetrile / Amygdalin as Cancer Treatment

Cutoff: 12 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.

## Consensus reports the178-patient nonrandomized regimen and explicitly limits original access to its abstract.
Our original abstract check agrees: practitioner-like metabolic programme, no substantive benefit and cyanide hazards. The175 evaluable/one temporary partial response detail is supplied by a later review in Consensus and by auxiliaryNCIcontext in our check; it is not directly verified in an original trial body. Do not call this an RCT or zero responses. [Original PMID7033783](https://pubmed.ncbi.nlm.nih.gov/7033783/). Access: abstract_metadata.

## Provider emphasizes negative clinical evidence but does not detail the original favorable case-record submission analysis.
The original1978 abstract retains six responses judged by a blinded oncology panel, while only presumed-success cases were solicited and incomplete records excluded. These observations justify interest without proving a treatment effect or becoming an independent controlled trial. [Original PMID683212](https://pubmed.ncbi.nlm.nih.gov/683212/). Access: abstract_metadata.

## Consensus correctly reports oral/IV differences and the raw-almond interaction from the original pharmacology abstract.
Original six-patient abstract confirms low observed toxicity withIVadministration, increased oral cyanide and transient symptoms in one almond-challenged patient. Small route-specific observations cannot prove safety of every IV dose or efficacy. [Original PMID7005480](https://pubmed.ncbi.nlm.nih.gov/7005480/). Access: abstract_metadata.

## Provider discusses clinically attainable exposure and oral versusIV activation.
Original pharmacology distinguishes high, briefIVparent plasma levels from very low oral parent levels with cyanide increase. These are parent plasma measurements, not sustained tumour concentration. Culturemg/mL activity cannot be equated to the same human exposure. [Original PMID7273266](https://pubmed.ncbi.nlm.nih.gov/7273266/). Access: abstract_metadata.

## Consensus acknowledges matched-normal positive studies but does not report the examined original cell-pair dose limits.
Original Results verifies HepG2 versusWI38 differentialIC50 and sorafenib synergy atmg/mL concentrations. Unmatched tissue types, cell proliferation and missing whole-organ exposure still limit a human therapeutic window; the positive comparator is retained. [Original PMID37726740](https://pubmed.ncbi.nlm.nih.gov/37726740/). Access: full_text_partial.

## Provider's preclinical summary could be read as broad monodrug activity.
Original body distinguishes minimal growth effect from1 mg/mLalone from strong sulforaphane-combination effects, and reports no induced apoptosis in those assays. A low dose in that protocol is not verified patient exposure. [Original PMID39519581](https://pubmed.ncbi.nlm.nih.gov/39519581/). Access: full_text_partial.

## Provider emphasizes nanocarriers as a technical advance rather than clinical validation.
Original magnetic-enzyme Results agree with a restricted delivery benefit and retain inactive targeting controls. AST, CK and LDHincrease despite no obvious organ histology injury. Neither the carrier norenzyme addition is historical free-drug therapy, and limited histology cannot be labeled complete safety. [Original PMID32636623](https://pubmed.ncbi.nlm.nih.gov/32636623/). Access: full_text_partial.

## Consensus supplies a new niosomal-gel animal lead and a provider release graphic.
Original record and selected Methods/Results were examined: thirty rats in small DMBA groups, topical loaded gel versus blank gel/oral free compound, reduced local carcinoma volume and skin pathology. These results remain positive in their context, but do not measure a human regimen, systemic cyanide margin or complete normal-organ safety. Provider graphics are not republished. [Original PMID36355478](https://pubmed.ncbi.nlm.nih.gov/36355478/). Access: full_text_partial.

## Consensus says alginate-chitosan carriers protect normal cells and tissues.
The original abstract reports release, mucin/flow and H1299 cell activity, then makes a broad protection conclusion. Our original-body access is unavailable, so an independent normal-tissue endpoint was not verified. Its abstract supports a delivery lead, not clinical proof of protection. [Original PMID32097740](https://pubmed.ncbi.nlm.nih.gov/32097740/). Access: abstract_metadata.

## Consensus separates alternative/complementary-care survival cohorts from laetrile-specific efficacy.
Original abstract agrees that refusal is important: mortality association becomes nonsignificant after refusal/delay adjustment. This observational attenuation is not randomized mediation proof, not a compound-specific hazard ratio and not evidence that every complementary use causes death. [Original PMID30027204](https://pubmed.ncbi.nlm.nih.gov/30027204/). Access: abstract_metadata.

## Provider uses refusal cohorts as separate evidence about treatment substitution.
OriginalMethods confirms retrospective primary-treatment refusal, limited age/year/stage matching and exclusion of older patients. The association is clinically relevant but cannot identify laetrile exposure or remove every selection factor. [Original PMID22734852](https://pubmed.ncbi.nlm.nih.gov/22734852/). Access: full_text_partial.

## Methods
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.